#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myeloid leukaemia Congenital aplastic anaemia Ovarian epithelial cancer Extra-osseous Ewing's sarcoma recurrent Intracranial germ cell tumour Prolymphocytic leukaemia Crigler-Najjar syndrome Cryoglobulinaemia Fontan procedure Dermatomyositis Non-small cell lung cancer recurrent Diabetes insipidus Partial lipodystrophy Ischaemic stroke Extra-osseous Ewing's sarcoma More trials…

    Learn about Rare Diseases

    Primary mediastinal large B-cell lymphoma – Life with Disease Ehlers-Danlos syndrome Mucous membrane pemphigoid Extranodal marginal zone B-cell lymphoma (MALT type) – Trials in Disease Mast cell activation syndrome – Basic Information Extranodal marginal zone B-cell lymphoma (MALT type) Chondrosarcoma metastatic – Diagnostics Burkitt’s lymphoma – Diagnostics Idiopathic inflammatory myopathy – Diagnostics Glomerulonephritis rapidly progressive – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    RIVASTIGMINE Imifoplatin Dexchlorpheniramine Maleate Tremelimumab Ecoo4 Saruparib Amantadine Hemisulfate [18F]DED Dalteparin Sodium Citicoline Sodium Bintrafusp Alfa Piromelatine Lisinopril Dihydrate Tiotropium Bromide [18F]-Altanserin Olopatadine 7-Ethyl-10-Hydroxycamptothecin Mdna11 Poltreg-T1D Verapamil Hydrochloride More therapies…

    Learn about Your Condition

    Intestinal infarction White matter lesion Ankylosing spondylitis High-grade B-cell lymphoma Osteotomy Porphyria non-acute Osteopenia Lymphoedema Dyspnoea Cancer fatigue Sepsis Alopecia areata Fontan procedure Multiple sclerosis Endocrine ophthalmopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Fakultna Nemocnica Trencín

Fakultna Nemocnica Trencín

Lxtojygswft 2tn Tkyzqfqr 9ei 0wo Snracfvf

Want to learn more about this study or check if you can participate? Contact us.

  • Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

    Recruiting

    3 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Lithuania Poland Slovakia +1

  • A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Aflibercept
    Bulgaria Czechia Hungary Latvia Poland Slovakia

  • Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ranibizumab
    Austria Belgium Bulgaria Croatia Czechia France +7

  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer
    • Breast cancer metastatic
    Investigated Drugs:
    • 2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
    • Everolimus
    • Exemestane
    Belgium Bulgaria Czechia Finland France Germany +8

  • Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

    Recruiting

    2 1
    Czechia Germany Hungary Poland Slovakia

  • Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hypertension
    • Chronic kidney disease
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Belgium Bulgaria Czechia Denmark France Germany +9

  • A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Age-related macular degeneration
    Investigated Drugs:
    • Fluorescein Sodium
    • Aflibercept
    Austria Croatia Czechia Denmark France Hungary +4

  • A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

    Not yet recruiting

    4 1 1
    Investigated Diseases:
    • Cachexia
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • Ponsegromab
    Belgium Bulgaria France Germany Italy Poland +2

  • Study of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

    Not yet recruiting

    3 1
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Diabetic retinal oedema
    Investigated Drugs:
    • Eye103
    • Fluorescein Sodium
    • Ranibizumab
    Austria Croatia Czechia France Germany Hungary +6
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!